| |
Fig. 5. Phenotype of miR-130a, miR-219 and miR-23b MO injections. A. Injection of miR-130a MO resulted in smaller eyes on the injected side (white and black arrows) in a dose-dependent manner. Histological sections showed that the different layers of the retina were not disturbed (black arrow). Control MO injection did not affect eye development. B. Loss of miR-130a function did not alter the expression of the pan-neural marker gene Sox3 at stage 13, but the expression of Rx1 and Pax6 (back arrows). C. MiR-130a MO injected embryos revealed a downregulation of Rx1 and Pax6 at stage 23 (black arrows), but no chance in the expression of brain marker genes. D. MiR-219 deficient embryos showed smaller eyes (white and black arrows) in contrast to the control embryos (Control MO). E. The injection of 20 ng miR-219 MO led to a reduced expression of Rx1 and Pax6 (black arrows), but not of Sox3 at stage 13. F. The expression of Rx1 and Pax6 (black arrows) at stage 23 was downregulated upon loss of miR-219, whereas Emx1, En2 and Krox20 were not affected. G. The injection of miR-23b MO resulted in the development of abnormal eyes which are completely deformed (white arrows). In many embryos, the RPE was not closed at the ventral side of the embryo (right panel). The quantitative representation shows that this effect was dose-dependent. H. Expression of Rx1, Pax6 and Sox3 at stage 13. Loss of miR-23b led to a slight reduction in Rx1 and Pax6 expression. Sox3 was not affected. I. MiR-23b deficient embryos showed a strong downregulation of Rx1 and Pax6 and a slight reduction of Emx1, En2 and Krox20 on the injected side at stage 23 (black arrows). For all experiments a quantitative representation is shown. n = number of independent experiments; N = number of analyzed embryos. |
